EFFECTS OF CYP2D6 AND CYP3A5 GENOTYPES ON THE PLASMA CONCENTRATIONS OF RISPERIDONE AND 9-HYDROXYRISPERIDONE IN KOREAN SCHIZOPHRENIC PATIENTS.

被引：0
|
作者：
Kang, R. [1 ]
Jung, S. [2 ]
Kim, K. [3 ]
Lee, D. [2 ]
Cho, H. [2 ]
Jung, B. [2 ]
Lee, M. [1 ]
Park, J. [3 ]
机构：
[1] Korea Univ, Coll Med, Dept Psychiat, Seoul 136705, South Korea
[2] Yangsan Neuropsychiat Hosp, Dept Psychiat, Yangsan, South Korea
[3] Korea Univ, Coll Med, Dept Clin Pharmacol & Toxicol, Seoul 136705, South Korea
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2009年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [31] Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients
    Buster Mannheimer
    Johan Holm
    Larissa Koukel
    Leif Bertilsson
    Urban Ösby
    Erik Eliasson
    European Journal of Clinical Pharmacology, 2014, 70 : 695 - 699
  • [32] Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients
    Mannheimer, Buster
    Holm, Johan
    Koukel, Larissa
    Bertilsson, Leif
    Osby, Urban
    Eliasson, Erik
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (06) : 695 - 699
  • [33] Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population
    Mutawi, Thuraya M.
    Zedan, Mohamed M.
    Yahya, Raida S.
    Zakria, Mahmoud M.
    El-Sawi, Mamdouh R.
    Gaedigk, Andrea
    PHARMACOGENOMICS, 2021, 22 (06) : 323 - 334
  • [34] Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients
    Chan, Sze Wa
    Chu, Tanya T. W.
    Ho, Chung Shun
    Kong, Alice P. S.
    Tomlinson, Brian
    Zeng, Weiwei
    FRONTIERS IN MEDICINE, 2021, 8
  • [35] Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans
    Krulikas, Linas
    Bates, Jill
    Chanfreau, Catherine
    Coleman, Heather
    Dalton, Shawn
    Voora, Deepak
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (02) : 390 - 396
  • [36] CYP3A5 but Not CYP2D6 Polymorphism Contributes Significantly to the Variability in Dextropropoxyphene Disposition
    Yin, Ophelia Q. P.
    Tomlinson, Brian
    Chow, Moses S. S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (10): : 1136 - 1141
  • [37] Effect of CYP2D6, CYP3A5, and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and Its Active Moiety
    Xiang, Qian
    Zhao, Xia
    Zhou, Ying
    Duan, Jing Li
    Cui, Yi Min
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (06): : 659 - 666
  • [38] Effects of CYP2D6 genotypes on pharmacokinetics and adverse reactions of risperidone in healthy volunteers
    Novalbos, J.
    Gallego-Sandin, S.
    Ladona, M. G.
    Higuero, A.
    Diez-Martin, L.
    Pelegrina, M. L.
    Garcia, A. G.
    Abad-Santos, F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 103 - 103
  • [39] Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
    Lim, Joanne S. L.
    Chen, Xiang A.
    Singh, Onkar
    Yap, Yoon S.
    Ng, Raymond C. H.
    Wong, Nan S.
    Wong, Mabel
    Lee, Edmund J. D.
    Chowbay, Balram
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (05) : 737 - 750
  • [40] CYP2D6, CYP3A5, and CYP3A4 gene polymorphisms in Russian, Tatar, and Bashkir populations
    O. E. Mustafina
    I. A. Tuktarova
    D. D. Karimov
    R. Sh. Somova
    T. R. Nasibullin
    Russian Journal of Genetics, 2015, 51 : 98 - 107
12345